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Summary 
Collagen type II-induced arthritis (CIA) is generated in susceptible rodent strains by intradermal 
injections of homologous orheterologous native type II collagen in complete Freund's adjuvant. 
Symptoms of CIA are analogous to those of the human autoimmune disease, rheumatoid arthritis. 
CIA is a model system for T cell-mediated autoimmune disease. To study the T cell receptor 
(TCR) repertoire of bovine type II-specific T cells that may be involved in the pathogenesis 
of CIA in DBA/1Lac.J (H-2q) mice, 13 clonally distinct T cell hybridomas specific for bovine 
type II collagen have been established and the ot and/3 chains of their TCRs have been analyzed. 
These T cell hybridomas recognize pitopes that are shared by type II collagens from distinct 
species and not by type I collagens, and exhibit a highly restricted TCP,.-ot/3 repertoire. The 
ot chains of the TCRs employ three Vot gene subfamilies (Votll, Vot8, and Vot22) and four 
Jot gene segments (Jot42, Jot24, Jot37, and Jot32). The Vot22 is a newly identified subfamily 
consisting of approximately four to six members, and exhibits a high degree of polymorphism 
among four mouse strains of distinct Vot haplotypes. In addition, the B chains of the TCRs 
employ three V/3 gene subfamilies (V~8, VB1, and VB6), however the V38.2 gene segment 
is preferentially utilized (58.3%). In contrast, he JB gene segment usage is more heterogeneous. 
On the basis of the highly limited TCR-ot/3 repertoire of the TCRs of the panel of bovine 
type II-specific T cell hybrid clones, a significant reduction (60%) of the incidence of arthritis 
in DBA/1Lac.J mice is accomplished by the use of anti-V38.2 antibody therapy. 
C ollagen type II-induced arthritis (CIA) 1 in animals is an experimental animal model system of the human au- 
toimmune disease, rheumatoid arthritis (1-3). CIA is induced 
in susceptible rodents by intradermal injections of homolo- 
gous or heterologous native collagen type II (1, 2). In con- 
trast, similar injections of other joint tissue proteins uch as 
collagen type I and proteoglycans do not lead to arthritis. 
In addition, susceptibility oCIA in rodents i linked to MHC 
genes (4, 5). Among the inbred mouse strains, only mice 
of the H-2q and H-2 r haplotypes generally acquire an inflam- 
matory polyarthritis upon immunization with collagen type 
II in CFA (5). However, SWR (H-2q) and RIII (H-2 r) in- 
bred mouse strains are resistant o CIA (6, 7), suggesting 
that non-MHC genes are also crucial for the induction of 
the disease. 
1 Abbreviations u ed in this paper: B.CII, bovine collagen type II; C.CII, 
chicken collagen type II; CIA, collagen type If-induced arthritis; EAE, 
experimental allergic encephalomyelitis; MBP,myelin basic protein; NOD, 
nonobese diabetic. 
Previous tudies indicate that CIA is associated with a high 
level of both cellular and humoral responses to collagen type 
II. However, the role of Abs and T lymphocytes in the patho- 
genesis of the disease is ill-defined. It has been reported that 
transfer of anti-collagen type II Abs to naive animals results 
in transient synovitis with a histopathologic pi ture different 
from that seen in CIA (8). Hence, antibodies to collagen type 
II alone are not sufficient for the development of the proto- 
typical esions associated with arthritis. In contrast, adoptive 
transfer of collagen type II Abs and CD4 T cells isolated from 
mice immunized with denatured collagen type II, can to- 
gether promote the development of dassical arthritis (9). This 
finding clearly demonstrates the synergistic effect between 
humoral and cellular esponses in initiating polyarthritis. The 
important role of CD4 T cells in the induction of arthritis 
is manifested indirectly by the in vivo administration f anti- 
MHC class II Abs, resulting in the inhibition of CIA (10). 
Moreover, direct involvement of T cells has been illustrated 
by the resistance of athymic nude rats, and anti-CD4 treated 
mice to CIA (11, 12). 
The analysis of TCRs of myelin basic protein (MBP)-reac- 
387 J. Exp. Med. 9 The Rockefeller University Press 9 0022-1007/93/02/0387/09 $2.00 
Volume 177 February 1993 387-395 
 o
n
 August 21, 2006 
w
w
w
.jem.org
D
ow
nloaded from
 
tive T cells derived from the experimental allergic en- 
cephalomyelitis (EAE)-susceptible B10.PL mice revealed that 
the TCR-o~/3 repertoire is highly restricted, using only two 
Vol gene segments (Vo~2.3 and Vc~4.2) and two V3 gene 
segments (V~8.2 and V313) (13). In addition, a similar finding 
has been obtained from T cell clones derived from PL/J mice 
and Lewis rats (14, 15). Consequently, the prevention and 
reversal of EAE in B10.PL mice was accomplished using a 
combination of anti-VB8.2 and anti-V313 mAbs (16). These 
surprising results have suggested that autoaggressive T cells 
in other autoimmune diseases may generally exhibit restricted 
TCR repertoires, and that anti-TCR therapies may prevent 
and/or cure autoimmune diseases. However, the notion that 
pathogenic T cells in autoimmune diseases exhibit limited 
TCR repertoires cannot be generalized to every autoimmune 
disease since molecular characterization f the TCRs used 
by islet-infiltrating T cells of nonobese diabetic (NOD) mice 
revealed that the usage of TCR V and J gene segments i
not restricted as in the case of EAE (17, 18). 
The question of whether or not the TCR repertoire of 
T cells involved in the induction of CIA is limited has been 
addressed indirectly by two different groups. The first group 
has found that DBA/1 mice treated with (a) anti-V38.1,8.2 
mAb (KJ16) and (b) anti-V35.1,5.2 mAb (MR9.4), before 
injections of bovine collagen type II (B.CII) had a reduced 
incidence of arthritis, 28.6 and 50%o, respectively, asopposed 
to an 84.6% incidence in control mice (19). This observa- 
tion suggests that T cells involved in the pathogenesis ofpoly- 
arthritis may exhibit a restricted use of TCR V3 chains (19). 
The second study has utilized a PCR technique to examine 
TCR V3 gene usage in cells obtained from the joints as well 
as LNs of B10.Q mice injected with chicken collagen type 
II (C.CII) (20). The authors observed that, whereas the joint 
T cells expressed VB2, V36, VB8.2, V/~9, VB10, and VB15 
transcripts, the LN cells showed V36, V38.2, and VB9 tran- 
scripts. Although there are at least six different VB gene sub- 
families expressed in the afflicted joints, and neither the 
specificity nor the clinical significance of the T cells expressing 
the above V~ gene elements i known, the authors claimed 
that there is restrictive usage of TCR V3 segments in CIA. 
The present study aims at determining in more detail the 
TCR-c~/3 repertoire of the T cell response to B.CII that may 
play an important role in the induction of arthritis in 
DBA/1Lac.J (H-2q) mice immunized with B.CII. 13 clonally 
distinct T cell hybridomas specific for B.CII have been estab- 
lished. These T cell hybridomas exhibit a highly restricted 
TCR-oJ3 repertoire. Accordingly, we were able to amelio- 
rate CIA disease in mice by the use ofTCR V38.2-specific Ab. 
Materials and Methods 
Mice. DBA/1LacJ, BALB/cJ, C57BL/6J, and SWR/J mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Establishment of RCIl-specific T Cell Hybridomas. Male DBA/ 
1Lac.J mice were immunized intradermally with 100/zg native B.CII 
(Elastin Products Company Inc., Owensville, MO) in CFA. In- 
guinal and popliteal LNs from three to four mice were removed 
10 d later, and a single cell suspension was made in a serum-free 
388 
medium (HL-1; Ventrex Laboratories, Portland, ME). Cells were 
plated at 4 x 106 cells per ml in a 24-well plate in the presence 
of 10/zg/ml B.CII for 3 d. T cells were expanded with IL-2 (20 
U/ml) (Genzyme Corp., Boston, MA) for 2 d. Activated T cells 
were then fused with the TCR-otlB negative variant of the AKR 
thymoma BW5147 (a kind gift of Dr. Bom, University of Colorado 
Health Sciences Center, Denver, CO), as described previously (21). 
A large number of hybrids were generated and screened for their 
reactivity against B.CII. These T cell hybridomas were then sub- 
cloned by limiting dilution (0.3 cell/well) and tested for their 
specificity against B.CII, C.CII (Genzyme Corp.), and B.CI (Sigma 
Chemical Co., St. Louis, MO) proteins. Stimulations of T cell 
hybrids were performed in triplicate 200-#1 cultures containing 10 s 
hybridoma cells, 3 x 103 DBA/1Lac.J splenocytes, and 2/zg col- 
lagen. After 24 h, culture supernatants were assayed for their ability 
to support he growth of 8 x 103 IL-2-dependent CTLL2 cells 
(American Type Culture Collection, Rockville, MD). Cell growth 
was assayed by the colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]- 
2,5-diphenyl tetrazolium bromide) (Sigma Chemical Co.) assay (22), 
and plotted as relative OD at 570/650 nm. I1_,2 production by T 
cell hybridomas was determined from a standard curve generated 
with known quantities of recombinant mouse II,-2. 
Flow Cytometric Analysis. The hybridoma F23.2 (mouse IgG1) 
specific for the mouse TCR V38.2 (23) was a gift of Dr. Bevan 
(University of Washington, Seattle, WA). Biotinylated F23.2 mAb 
was a gift of Dr. Goverman (Caltech, Pasadena, CA). The hybridoma 
44.22.1 (rat IgG2a) specific for the mouse TCR V~6 (24) was a 
gift of Dr. Hengartner (Institute for Pathology, Zurich, Switzer- 
land). The purified F23.2 and 44.22.1 mAbs were purified from 
ascites fluid on protein G membranes (Amicon Corp., Beverly, MA). 
The hybridomas KT50 (rat IgG2a) and KT65 (rat IgG2a) specific 
for the mouse TCR V38 (25) were a gift of Dr. Tomonari (Med- 
ical Research Council Clinical Research Centre, Harrow, Middlesex, 
UK). The hybridoma RRS-1 (rat IgG) specific for the mouse TCR 
V~11 (26) was provided by Dr. Kanagawa. 106 T cells were stained 
with an anti-TCR V mAb supernatant followed by a FITC-con- 
jugated goat anti-mouse IgG or goat anti-rat IgG Abs (Organon 
Teknika Corp., Durham, NC) and then subjected to flow cyto- 
metric analysis using a flow cytometer (50H Cytofluorograph; 
Ortho Diagnostic Systems Inc., Westwood, MA) as described pre- 
viously (16). To determine the efficiency of in vivo depletion of 
T cells expressing TCR V/38.2, mice were given intraperitoneal 
injections of the F23.2 mAb (0.5 mg purified Ab per mouse). 
Draining LNs were removed 3 d after injection, a single cell sus- 
pension was made, and RBCs and dead cells removed using a 
lympholyte-M gradient (Cedarlane Laboratories Ltd., Hornby, On- 
tario, Canada). To reduce background staining due to nonspecific 
binding, 106 lymphoid cells were resuspended in PBS containing 
0.02%0 NAN3, 2% normal mouse serum, and anti-CD32 mAb 
(Pharmingen, San Diego, CA). Lymphoid cells were stained with 
a biotinylated F23.2 mAb followed by a FITC-conjugated anti- 
mouse CD3 Ab (Boehringer Mannheim Biochemicals, Indianapolis, 
IN), and R-PE-conjugated avidin (Caltag Laboratories, San Fran- 
cisco, CA). Lymphoid cells were then subjected to flow cytometric 
analysis using a flow cytometer (Epics Elite; Coulter Electronics 
Inc., Miami, FL). 
Southern Blot Analysis. Southern blot analysis was carried out 
as described previously (27). The probe used to identify the Vc~22 
gene subfamily was made from the PCR product obtained from 
the amplification of a cDNA clone containing the TCR c~ chain 
gene of the 57.7 T cell hybridoma using two primers derived from 
the Voe22.1 gene segment: he sequence of the 5' primer was 5' 
CCGAATTACTTCTGGTGGTAC 3' whereas the sequence ofthe 
3' primer was 5' TGCTGCTGCACAGAAGTAGAT 3'. 
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PCR Amplification a d Sequence Analysis. Total cellular RNA 
were isolated from the B.C II-8pecific T cell hybridomas (28). First- 
strand cDNA synthesis ofTCR ce or 3 chain gene was performed 
using Ca primer (5' AGAGGGTGCTGTCCTGAGAC 3') or C3 
primer (5' GCCAAGCACACGAGGGTAGCC 3'). The reverse 
transcription reaction was performed in a DNA thermal cycler 
(Perkin-Elmer Cetu8 Corp., Norwalk, CT). The synthesized first- 
strand cDNA containing TCR.-ce or -13 was then used as a tem- 
plate for the PCR amplification reaction. To amplify unknown Vc~ 
and V3 genes expressed by the T cell hybridomas, three 5' con- 
sensus Vce primers (5' VaA: 5' CTTCTGGTGGTACAGACA 3', 
5' VceB: 5' TCCTTTTC'I'GGTATGTGCA 3', and 5' Vc~C: 5' 
AGCTGCAGTGGTTCCAACA 3'), and a single 5' consensus V3 
primer (5' AR'GTACTGGTATCAGCAG 3') were designed from all 
known Vc~ and V3 gene segment sequences and used with the 
above Cc~ and C3 primers. After amplification, T4polymerase was 
then added and incubated at37~ for 10 min. The PCR-amplified 
TCR-c~ or -3 gene product was electrophoresed through 1.2% low- 
melting agarose gel and the DNA corresponding to the predicted 
size was isolated. The purified fragment was phosphorylated with 
a polynucleotide kinase and cloned into a blunt-ended &phosphor- 
ylated M13mp8 vector. Recombinant M13 were isolated and DNA 
sequence analysis was performed using the chain termination method 
(Sequenase v rsion 2.0 kit; U.S. Biochemical, Cleveland, OH). 
Results 
Characterization fB, CII-specific T Cell Hybridomas. B.CII- 
reactive T cell hybrids were generated from three separate 
fusions. 13 were subdoned by limiting dilution (0.3 cell/well) 
for this study and their TCR oL and 3 chain genes were sub- 
jected to sequence analysis. These T cell hybridomas were 
tested for their specificity against the B.CII, C.CII, and B.CI 
proteins. As shown in Fig. 1, all hybrids responded to both 
B.CII and C.CII, but not to B.CI. The low response of hy- 
bridoma 92 is due to the frequent loss of chromosomes n- 
coding its TCR c~/3 chains in culture. Attempts to isolate 
a 92 hybridoma subclone xpressing a high level of TCRs 
by limiting dilution has failed. These results indicate that the 
TCRs of these T cell hybridomas recognize conserved epi- 
topes that are shared by type II collagens from different spe- 
cies and not by type I coUagens. Hence, the T cell hybrids 
are protein type specific but not species pecific. 
Sequences ofthe TCR cr/~ Chain Genes. To examine het- 
erogeneity of the T cell response to B.CII in CIA autoim- 
mune disease, the TCR-oJ3 genes of the 13 B.CII-specific 
T cell hybridomas were subjected to sequence analysis using 
a sensitive and rapid PCR technique. On the basis of con- 
served 5' DNA sequences present in all known Vo~ and VB 
gene segments, we designed 5' Vo~ and 5' VB oligonucleo- 
tide primers and used them with 3' constant region Co~ and 
and 3' constant region C3 primers, respectively, to amplify 
cDNA from B.CII-specific T cell clones expressing unknown 
TCR V region genes (see Materials and Methods). These T 
cell hybrids have been derived from different mice and three 
independent fusion experiments, and therefore, the T cell hy- 
bridomas are a representative panel of B.CII-specific T cell 
clones. 
T cell clones can be divided based on Vot gene segment 
usage into three groups (Fig. 2). The first group employs 
o 
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Figure 1. Response of the T cell hybridomas to B.CII, B.CI, and C.CII. 
Stimulations of T cell hybrids were performed in triplicate 200 #1 cultures 
containing 103 hybridoma cells, 3 x 10 s DBA/1LacJ splenocytes, and 2 
/~g collagen. After 24 h, culture supernatants were assayed for theiz ability 
to support the growth of 8 x 103 Ib2-dependent CTLL2 cells in 96 mi- 
crotiter plates. Cell growth was assessed after 24 h of culture by the colori- 
metric MTT assay and is plotted as relative OD at 570/650 rim. Units 
of IL-2 were deduced from the equation ofa straight line (2, = 56,103 
+ 212.51 log x, where y = absorbance U at 570/650 nm and x = Ib2 
U) of a standard curve generated with known quantities of recombinant 
mouse Ib2. 
two members of the Vot11 subfamily (",'8-10 Vot members), 
Vot11.1 a, and Vot11.1 b. The difference between Vot11.1 a and 
Vet11.1 b regions is 11 nucleotides at the DNA level, and 
only five amino acids at the protein level. Because of the ex- 
tensive homology between Vodl.1 ~ and Vot11.1 b gene seg- 
ments, the Vc~11.1 b gene segment was considered previously 
as an allele to the Va11,1 ~ gene segment (26). Hence, the 
presence of both Va11.1 ~ and Vot11.1 b gene segments in the 
DBA/1Lac.J genome, unequivocally indicates that they are 
not two allelic forms of the same gene segment, but rather 
two different members of the Vot11 subfamily. Consequently, 
a new nomenclature is proposed for these two gene segments: 
Vcdl.1 and Vodl.4 to replace the old nomenclature, 
Vot11.1 aand Vcdl.1 b, respectively. As noted in Fig. 2, two 
Jo~ gene segments (,Ja42 and Jor were used in this group. 
The Jot42 segment is a newly identified functional Joe (29) 
and is preferentially selected by the rearranged Va11.1, 11.4 
gene segments (five of seven). In the second group, all three 
389 Osman etal. 
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T-Cell Vu N Ja  Vfl N-Dfl-N J~ 
Clone 
u F C A A E A S S S F S K L V F F C A S A P D R G G E R L F F 
173 TACI'I'CI~T GC TCCIV=AG C~.ATC C TCC T ~ CA ~ CCI~ ~T T TTCTGTGCCAGCG CCCCGGACAGC-GGTGG CGAAAGA~AmTnC 
Vall.l Ju42(new) ~8.2  Dill Jill.4 
Y F C A A E A S S S F S K L V F F C A S A P D R W Q R L F F 
10S TACTTCTGTC~TGCTGAG GCATCCTCCTCCTTCA~ TTC~CAGCG CCCCC-C, ACAGGTGGCAG AGATTAI-I-I-rfC 
Vall .i Ju42(new) V~8.2 D~I Jill .4 
Y F C A A E A S S S F S K L V F F C A S S Q V G N Q D T Q Y F 
BL~@ TACTTCTGTGCTGCTGAG GCATCCTCCTCCTTCAC~C~ TT~C-CA~CAA GTGGGG AACCAAGACACCCAGTACTTT 
VulI.I J(~42(~ew) V~I Dil2 Jil2.5 
Y F C A A E T S S S F S K L V F L C A S S R T A N T G Q L Y F 
IM .4  TACTTCTGTGCTGCTGAG A CATCC TCCTC~GCAAGCTGGTGTIT  CTCTGTGCCAGCAGC CGGACAGCA AACACCC42-GCAGC TCTACTTT 
Vul1.4 Ju42(new) V~6 Dill J~2.2 
Y F C A A D T S S S F S K L V F F C A S E A V N S G N T L Y F 
255.4 TACTTCTGTGCTGL~ TA CATCCTCCTCCTTCAGCAAGCTGGT~ TTCTGTGCCAGCG AAGQA_~TTAAT TCTGGAAATACGCTCTATTTT 
VuII. 4 do42(new) V~8.2 Dill Jill. 3 
Y F C A A E T G G A D R L T F F C A S G D R A L S Y N S P L Y F 
92 TACTTCTGTC~TGCTGAG ACAGGAGGTGCAGATAGACTCACC~ TTCTGTGCCAGCGGTGAT ~CAC~ TCCTATAATTC GCCCCTCTACTTT 
Vull.1 J~37 ~8.2  Dill Jill.6 
u F C A A E T G G A D R L T F F C A S S G G Q G R Y A E Q F F 
Bl12 TACTTCTGT~CT~CTGAG ACAGGAGGTGCAGATAGACTCACCTTT TTCTGTGCCAGCAGTG GGGGACAGC~GA TATGCTGAGCAGTTCTTC 
Vull. 1 Jo37 Vil8.3 Dill Jil2.1 
Group 1 
u F C A L R D N N R I F F F C A S G D V D S A N S D u T F 
181.2  TACTrCTGTC~T~G GGA CAATAACAGAATCTTCTTT TI~TGTC-CCAGCC~TGATG T C~ACAGTC~A AACTCCGACTACACCTTC 
Y~*8. 4 J~24 V~8. 2 Dill J~ l . 2 
Y F C A L R D N N R I F F F C A S G D V D G A N S D Y T F 
2tl.t TAeerc~crrr~G c~ c~T~c~c~',rrcrrr rrc~iv, ceA~c~Tca~ ~c~ec~c-c~ ~c~cec~cT~c~ccerc 
vaS. 4 da24 V~8. 2 Dill Jill.2 
Y F C A L R D N N R I F F 
55.3  TACTTCTGTGCTTTGAG GGA CAATAACAGAATCTTCTTT 
VuS. 4 Ju24 
Group 2 
Y F C A A A I N N A G A K L T F F C A S G D T A G A N E R L F F 
57.7  TACTCCTGTGC.AGCAGCA AT TAATAATGCAGGTGCCAAGCTCACATTC TTCTGTGCCAGCGGTGAT ACGGCAGGGG CCAACGAAAGATTA'rFp~C 
VU22,1 (new) Jo32 V~8.2 Dill Jill. 4 
u F C A A A I N N A G A K L T F F C A S S Q D F W N T L Y F 
278 TACTCCTGTGCAGCAC-CA AT TAATAATGCAGGTGC AAGCTCACATTC TTTTGTGCCAGCAGCCAA GACTTCTGG AACACCTTGTACTTT 
VU22. I ( new ) Ju32 V~ l Dil2 J~ 2. 4 
Y F C A A L N N N R I F F F C A S S L Q P G Q N S G N T L u F 
HI31  TACTCCTGTGCAGCA CTTAA CAATAACAGAATCTTCTTT TTI'I~TC42CAGCAGCC TCCAACCGGGACAGAAT TCTGGAAATAC C-CTC TATTTT 
VU 2 2 .1 (new) Ju 2 4 Vil l Dill Jill. 3 
Group 3 
Figure 2. Nucleotide and amino acid sequences of Va-Jo~ and VB-Dfl-J~ junctional regions of the TCK oe and fl chain genes expressed by13 T 
cell hybridomas specific for B.CII. On the basis of the TCR c~ chain usage, the T cell hybrid clones were divided into three groups. The 3' boundaries 
of Vol 11.1, Va 11.4, Va 22.1, and Vfll gene segments were arbitrarily determined since germline sequence informations are not yet known. The 
remains of the germline Dill (5' GGGACAGGGGGC Y), and DB2 (5' GGGACTGGGGGGGC 3') sequences are underlined. Nucleotides between 
Va and Ja as well as Vfl, D3, and J3 are proposed N region insertions. The predicted amino acid sequence is given above the nucleotide s quence 
using the single letter code. 
T cell clones hare the same Vo~8.4 and Joe24 gene segments. 
The Vo~8.4 gene segment isa member of the Va8 subfamily 
which consists of ~o8-10 members (30). Finally, the third 
group uses a new Vo~ gene segment, Vol22.1, which is dis- 
tinct from the other 21 Vo~ subfamilies that have been previ- 
ously described (Wang, K., J. L. Klotz, G. Kiser, G. Bristol, 
E. Lai, E. Gese, M. Kronenberg, and L. Hood, manuscript 
in preparation). A partial sequence of the Voe22.1 gene is 
given in Fig. 3 A. Genomic Southern blot analysis was per- 
formed to estimate the size of the newly identified Vo~22 gene 
subfamily and to study the RFLP pattern among four inbred 
mouse strains of distinct Vo~ haplotypes: BALB/c (Voea), 
C57BL/6 (Vab), SWR (Vo~c), and DBA/1 (Vc~ a) (26, 31). 
The result indicates that the Vo~22 subfamily consists of ap- 
proximately four to six members (Fig. 3 B). In addition, the 
Va22 gene subfamily exhibits a high degree of polymorphism 
as indicated by the RFLP patterns generated using EcoRI 
and BamHI restriction enzymes (Fig. 3 B). 
As shown in Fig. 2, the first group employs three V~ gene 
subfamilies, V31, V36, and V38. Two members of the V38 
subfamily were used, V38.2 and V~8.3. However, the V38.2 
gene segment was found to be preferentially utilized (four 
of seven). Furthermore, seven distinct J3 gene segments of 
the available 12 functional J3 gene segments were used by 
the TCRs of the B.CII-reactive T cell hybridomas. Thus, 
unlike the biased V38.2 gene segment usage in this group, 
the use of J3 gene segments i more heterogeneous. In the 
second group, the T cell hybrid clones hare the same VB8.2 
andJ31.2. Finally, the third group uses V31 and V38.2 gene 
segments and three distinct J3 gene segments. 
vol-jot and vfl-Dfl-Jfl Junctional Regions. A comparison 
of the nucleotide and predicted amino acid sequences of the 
TCR oe/3 chain junctional regions expressed by B.CII-specific 
T cell hybridomas (Fig. 2) reveals that there is a strong selec- 
tion for highly conserved V~x-Jo~ junctional regions within 
each group. In contrast, VB-D3-J3 junctional regions are 
generally diverse (Fig. 2). Another interesting observation 
is that several TCRs share an identical oe chain in association 
with different 3 chains, e.g., clones 105, B120 (Vc~ll.1/V38.2 
and Vall.1/V31), clones 57.7, 278 (Vo122.1/V38.2 and 
Vo~22.1/V31), and clones 92, Bl12 (Vc~ll.1/VB8.2 and 
Voell.1/V38.3). This indicates the strong in vivo selection 
by the antigen for either a particular oe chain or a combina- 
tion of both o~ and 3 chains. 
Prevention of CIA in DBA/1LacJ Male Mice Using mAbs 
Specific for TCR V~ Chains. Since o~ and ~ chain sequences 
390 A Limited T Cell Receptor Repertoire inCollagen-induced Arthritis 
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Figure 3. Partial nucleotide and predicted amL~o acid sequences of Vo122.1 
region gene, and genomic Southern blotanalysis of the Vc~22 gene sub- 
family. (.,4) Partial nucleotide and predicted amino acid sequences of Vc~22.1 
cDNA clone derived from 57.7 T cell hybridoma specific for B.CII. Regions 
corresponding to Vc~, Jc~, and Cc~ are indicated. The 3' boundary of the 
Vc~22.1 gene segment was arbitrarily determined since germline sequences 
of this new V~ subfamily are not yet known. Nucleotides between Vc~ 
and Jc~ gene segments are proposed N region insertions. Th  predicted 
amino acid sequence is given above the nucleotide sequ nce using the single 
letter code. The nucleotide sequence data will appear in the EMBL, Gen- 
bank, and DDBJ Nucleotide Sequence Databases (accession number 
X67949). (B) Genomic DNA were obtained from livers of BALB/c, 
C57BL/6, DBA/1Lac.J, and SWR./J mice. "~10 #g of EcoRI or 
BamHI-digested DNA was electrophoresed through a 0.7% agarose gel, 
transferred toa zeta-probe membrane, hybridized with a labeled Vc~22.1 
probe, and exposed to an x-ray film for 3 d at -80~ with an intensifying 
screen. 
' 
Background 
9 ~ Background A~V~6 
.~ L Background J I" Background ~ F Background 
L v~e.2 j 
o 
t 
I-" Background - I  ~ Va11.1 V~S 
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Figure 4. Cell surface expression of VB8.2, VB6, and V~11.4 chains 
by a representative panel of T cell hybridomas specific for B.CIIand the 
in vivo depletion fDBA/1Lac.J LN cells expressing TCR VB8.2 chain 
after intraperitoneal injection of F23.2 mAb. (A-H) T cell hybridomas 
255.4, 136.4, H131, 278, B120, 105, and 55.3 were subjected to TCR 
surface xpression analysis using fluorescence flow cytometry. The cells 
were stained with the mAb F23.2, 44.22.1, RRS.1, KTS0, KT65, or anti- 
CD3 mAb followed by FITC-conjugated goat anti-mouse IgG or FITC- 
conjugated goat anti-rat IgG Abs. Background fluorescence represents 
staining of T cells with the FITC-conjugated Ab alone. Each histogram 
represents the analysis of 10,000 cells. (I and./') DBA/1Lac.J mice were 
injected with 0.5 mg i.p. F23.2 Ab. LN cells were removed after 3 d from 
treated mice (]) as well as normal mice (/) and stained with both biotinylated 
F23.2 and FITC-conjugated anti-CD3 mAbs in the pres nce ofanti-CD32 
mAb followed by R.-PE-conjugated avidin. Thetwo-color staining data 
are presented as ual-parameter contour plots in which increasing green 
fluorescence intensity (CD3) is plotted on the x axis versus increasing red 
fluorescence intensity (VB8.2) on the y axis. The percent values are the 
result of calculating the percentage of ll cells within the region ofinterest. 
of the TCRs of B.CII-specific T cell hybridomas have estab- 
lished that only three TCR V3 gene subfamilies (V3I,  V~6, 
and V~/8) and three TCR Vo~ subfamilies (Vcr Vcr and 
Vc~22) are employed, an examination ofwhether mAbs specific 
for TCR c~ chains and/or B chains can prevent C IA in mice 
was conducted. Although mAbs specific for TCR V36, V~8, 
Vow8, and Vol l l  are available, anti-TCR VoeS, as well as anti- 
TCR Vod l  Abs, are poorly characterized because of the com- 
plexity of both Vow8 and Vo~11 gene subfamilies ('~8-10 
members each). Before pursuing our specific immune inter- 
vention experiment, he reactivity pattern of a panel of the 
391 Osman et al. 
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available mAbs against the B.CII-specific T cell hybrids was 
determined. The F23.2 mAb stained all T cell clones expressing 
TCR Vf18.2. A representative of the T cell clones expressing 
TCR V~/8.2 is shown in Fig. 4 A. In addition, 44.22.1 mAb 
recognized the TCR VB6 chain expressed by the clone 136.4 
(Fig. 4 B). By contrast, neither F23.2 nor 44.22.1 recognized 
TCR B chains displayed by the clones H131, 278, and B120 
(Fig. 4, C-E). This is consistent with the DNA sequence 
data (Fig. 2), indicating that the three clones express the TCR 
V~I chain gene. The Ab RRS-1 stained the T cell clones 
expressing the TCP,. Va11.4, but not the TCR Va11.1 (Fig. 
4, F and G). Finally, KTS0 and KT65 mAbs specific for the 
TCR Vow8 chain failed to recognize the TCR. Vo~8.4 chain 
that is employed by three distinct T cell clones (Figs. 2 and 
4 H). Therefore, neither anti-Vow11 nor anti-Vow8 mAbs can 
be used in our attempt to block CIA since both Abs failed 
to recognize the corresponding TCRs displayed by the majority 
of B.CII-reactive T cell hybrid clones. Therefore, the anti- 
VBS.2 and the anti-Vfl6 are the mAbs of choice for interven- 
tion experiments since neither anti-V~l nor appropriate anti- 
Va mAbs are yet available. 
T cells reactive with the F23.2 mAb comprise 8-9% of 
T lymphocytes in the LNs of a normal DBA/1Lac.J mouse 
(Fig. 4/).  To examine the efficacy of in vivo depletion of 
T cells expressing TCR VBS.2, an intraperitoneal injection 
of 0.5 mg F23.2 Ab per mouse was found to be extremely 
effcient in eliminating virtually all TCR. V~8.2-bearing T 
cells in LNs after 3 d (Fig. 4J). The first question addressed 
was whether CIA can be blocked in DBA/1Lac.J mice with 
anti-V~8.2 Ab treatment. Mice received anti-Vfl8.2 Ab treat- 
ment wice: initially, 3 d before the intradermal primary im- 
munization with B.CII in CFA, and the second time before 
the intraperitoneal boost on day 21. As shown in Table 1, 
only 6 of 20 mice treated with anti-VBS.2 Ab developed ar- 
thritis (30%), whereas 18 of 20 mice in the untreated group 
(90%), as well as 9 of 10 mice in the mouse IgG1 (MOPC21) 
treated group (90%) developed chronic polyarthritis. 
Second, we were interested in examining whether mice 
treated with both anti-V~8.2 and anti-V~6 Abs would ex- 
hibit a reduced incidence of arthritis as compared with those 
pretreated with anti-V~8.2 Ab alone. Table 1 indicates that 
there is no significant difference between mice that received 
anti-VflS.2 Ab alone and those given anti-Vfl6 together with 
anti-V~8.2 Abs. Evidently, anti-VB8.2 Ab treatment alone 
is suffcient o reduce the incidence of arthritis by 60% in 
DBA/1Lac.J mice immunized with B.CII. 
Discussion 
CIA in mice is MHC class II restricted and a CD4 T cell-de- 
pendent autoimmune disease (10, 12). CIA resembles human 
rheumatoid arthritis in many clinical, histological, and im- 
munological respects. These remarkable similarities make CIA 
an ideal model system for study. The experiments described 
in this report endeavored todetermine the TCR-a/~ reper- 
toire in the CIA autoimmune disease model. 13 clonally dis- 
tinct T cell hybridomas specific for B.CII have been estab- 
lished, and the cx and ~ chain gene usage of their TCILs have 
been determined. 
The T cell hybridomas recognized conserved epitopes, 
present only in collagen type II molecules from different spe- 
cies, and exhibited alimited TCR-oJB repertoire. Although 
T cell clones displayed three TCR ~/chains (Vfl8, VBI, and 
Vfl6), the VflS.2 gene segment is preferentially employed 
by the B.CII-specific T cell hybrid clones (58%) (Fig. 2). 
Unlike the Vfl gene segment usage, the Vfl-Dfl-Jfl junctional 
regions utilized are more heterogeneous (Fig. 2). Therefore, 
the repeated usage of two Vfl gene segments (VB1, 25% 
and VBS.2, 58.3%), since both Vfl6 and Vf18.3 were used 
only once, strongly indicates that the TCR-B repertoire of 
Table 1. Inhibition of CIA in DBA/ILac.J Male Mice Using anti-TCR fl Chain Abs 
Average severity 
Antibody CIA incidence in afflicted mice 
treatment (%) mean _+ SD Day of onset 
None* 18/20 (90)* 3.94 _+ 0.89 s 4911 
Mouse IgG1 (MOPC21) 9/10 (90) 3.89 _+ 0.33 49 
Anti-VBS.2 6/20 (30) I 3.00 _+ 0.63 56 
Anti-VB8.2 plus anti-VB6 7/20 (35)** 3.42 _+ 0.97 56 
* Four groups of DBA/1Lac.J male mice were treated intraperitoneally with the corresponding Abs (0.5 rag/mouse), and immunized 3 d later in 
the base of the tail with 100/~g of B.CII in CFA. On day 18, mice received another Ab treatment. Mice were challenged intraperitoneally with 
100/~g B.CII in 100 mM acetic acid on day 21 and observed every other day for signs of arthritis. 
* Number and percentage of mice that developed chronic polyarthritis. 
s Average clinical severity of mice with arthritis. Clinical severity ineach affected paw is graded as: 0, normal; 1, redness and swelling; 2, defor- 
mity; 3, ankylosis. The scores were added to obtain the maximum arthritic score per mouse. 
II The first day of detecting clinical symptoms ofarthritis in mice. Mice were observed for the development of arthritis for up to 90 d. 
I/~ <0.01 when compared with the nontreated group using )r test with Yates correction. 
**p <0.01 when compared with the nontreated group using X 2 text with Yates correction. 
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the panel of the T cell hybridomas studied here is highly re- 
stricted. One plausible xplanation for these highly restricted 
VB gene segments with diverse V~D~-J~junctional regions 
is that the amino acid residues of VB1 and V/~8.2 regions 
and not the J~/, D~, or N region residues are primarily respon- 
sible for the interaction with collagen peptide-MHC com- 
plexes. In addition, of the three Vc~ gene subfamilies used 
by the TCRs of B.CII-reactive T cell hybridomas (Vo~11, V~8, 
and Vc~22), the Vo~11 gene subfamily is preferentially uti- 
lized (54%). Based on the Vol gene segment usage, the TCR 
cr chains of the T cell clones are divided into three groups. 
Within each group, Vc~-Jc~ junctional regions are highly con- 
served. Considering the powerful diversification mechanisms 
available for the TCR ot/~ chain genes, it is therefore obvious 
from the repeated usage of a few Vo~ gene segments (Vo~11.1, 
11.4, Vol8.4, and Vc~22.1) of the estimated 100 distinct Vc~ 
gene segments available for the TCR.s, that the B.CII as an 
antigen selects a restricted number of Vo~ gene segments. An- 
other important point is that the selection of a particular Vo~ 
gene segment from a Vol subfamily that shares an extensive 
homology with the other muhimembers of the same sub- 
family provides further evidence for the restricted use of Vc~ 
gene segments in the TCRs of the panel of B.CII-specific 
T cell hybrid clones. Similarly, the repeated employment of
a few Jo~ gene segments (Jo~42, Jo~37, Jol24, and Jol32) of 
the available 40-50 functional Jo~ gene segments, trongly 
indicates that heJc~ gene segment usage is also very restricted. 
Therefore, these results provide a compelling evidence for an 
exceedingly limited usage of V~, Vc~, and Jc~ gene segments 
in the TCRs of B.CII-specific T cell hybridomas. 
The resistance ofthe SWR mouse strain of the susceptible 
MHC haplotype (H-2q) to CIA has been assigned either to 
its genomic deletion of 50% of the TCR. VB gene segments, 
indicating the lack of expressing crucial VB genes (32), or 
to the deficiency ofthe C5 complement component (33). Our 
data demonstrating the effectiveness of anti-TCR V~8.2 Ab 
therapy in preventing CIA in DBA/1Lac.J mice, strongly sug- 
gest that the resistance of SWR mouse to arthritis may be 
due at least in part to the genomic deletion of the V~8.2 
gene segment. 
Akin to the EAE autoimmune disease model, CIA uti- 
lizes a highly restricted TCR-cff~ repertoire and affords an 
opportunity for testing aspecific immune manipulation. In 
establishing successful treatment ofEAE, several specific im- 
mune intervention tactics were applied to eliminate or inac- 
tivate autoaggressive T cell clones. Among these approaches 
are: (a) the vaccination of Lewis rats against EAE by the use 
of synthetic peptides derived from either the hypervariable 
regions II or III of the TCR V~/8.2 chain (34, 35); (b) the 
utilization of soluble class II MHC-MBP peptide complexes; 
prevention of EAE in SJL mice was accomplished by the in- 
travenous injections of soluble complexes consisting of en- 
cephalitogenic peptide 91-103 of MBP and MHC class II 
(I-A s) protein (36); and (c) the prevention of EAE in B10.PL 
mice by the use of a combination of anti-VB8.2 and anti- 
VB13 mAbs to eliminate the pathogenic T cells (16). Em- 
ploying these therapeutic means towards CIA may prove to 
be successful. However, the first and second approaches are 
393 Osman etal. 
limited in their use because of required apriori knowledge. 
In the case of immunization with peptides derived from the 
TCR VB8.2, it is assumed that the host will elicit an im- 
mune response against that peptide, however this is not always 
the case since certain hosts may not be responsive to given 
peptides. As for using soluble MHC-peptide complexes, the 
identification of all different pathogenic T cell epitopes i  a 
prerequisite. Since the anti-TCR Ab approach isnot limited 
in the above respects, we believe that anti-TCR Ab therapy 
is an effective, therapeutic approach in preventing CIA as we 
have recently demonstrated in the case of EAE (16). 
On the basis of the limited heterogeneity of the TCR c~/3 
chains employed by the panel of T cell hybrid clones described 
here, examination of whether anti-TCR Ab therapy resuhs 
in preventing the development ofchronic polyarthritis, as in 
the case of the EAE autoimmune disease model, was pos- 
sible. From our findings, it is evident hat the anti-V38.2 
Ab treatment is significant in reducing the incidence of ar- 
thritis by 60% in DBA/1Lac.J mice immunized with B.CII, 
whereas the anti-V36 Ab treatment does not result in any 
significant reduction of the disease incidence. One possible 
explanation for the failure of anti-V/~6 treatment in reducing 
arthritis in mice, is that B.CII-specific V/~6-expressing T cells 
may not play a clinically significant role in the induction of 
arthritis in mice. Another possibility isthat the anti-VB6 mAb 
which is a rat IgG2a mAb, may not be effective ineliminating 
all VB6-bearing T cells as compared with the effective anti- 
VB8.2 mAb (mouse IgG1). Furthermore, it is not dear why 
some mice developed arthritis in spite of anti-V/~8.2 treat- 
ment. One prospect is that these mice expand some other 
autoaggressive V3 TCR-bearing cells because of the pres- 
ence of a microenvironmental factor such as a bacterium or 
a virus. According to our sequence data, potential candidates 
are those expressing TCR V31 chains. Unfortunately, anti- 
V31 Ab is not available, and hence, it is not possible to ex- 
amine the above prospect. Nonetheless, attempts to raise this 
Ab and to characterize the TCRs of the pathogenic T cell 
subset in the anti-V38.2 treated mice are currently inprogress. 
In an attempt to address the issue that has been raised by 
Banerjee t al. (6) that certain TCR V3 genes uch as those 
which are deleted in the SWR mouse strain (37) play an im- 
portant role in the induction of arthritis, Goldschmidt e al. 
(39) studied the effect of anti-TCR Ab treatment on CIA. 
They reported that the in vivo administration f anti-VB8.1, 
8.2 or anti-V36 Ab did not result in any significant altera- 
tion of CIA in DBA/1 mice immunized with rat collagen 
type II. In addition, their analysis of T cells obtained from 
Ab treated mice on day 21 revealed that 50% of V/~8.1, 8.2- 
expressing T cells reemerged (38). Consequently, the efficiency 
of the Ab treatment in diminating V38.1,8.2-bearing T cells 
may account for the discrepancy between Goldschmidt group's 
and our findings. It is important to recall that in our study, 
mice received anti-V/38.2 Ab therapy twice; initially, 3 d be- 
fore the primary immunization a d the second time, on day 
18. The rationale for this regimen isto ensure avery efficient 
depletion of VB8.2-expressing T ceils over a long period of 
time. Therefore, the successful inhibition of CIA in DBA/1 
mice may hinge upon the efficacy of the Ab treatment in
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eliminating the autoaggressive V38.2-bearing T cells. A similar 
observation has been documented by Chiocchia et al. (19). 
In conclusion, analysis of the TCR oe/B chains of our panel 
of B.CII-specific T cell hybridomas has demonstrated that 
the TCR-od~ repertoire is limited towards the utilization 
of a few Vo~ and V3 gene segments. Furthermore, the anti- 
TCK therapy was found to be a very effective approach to 
significantly reduce the incidence of arthritis in DBA/1Lac.J 
mice. Nevertheless, a complete understanding of the molec- 
ular basis of the immune recognition i  CIA depends fully 
upon the identification and characterization f different patho- 
genic collagen II peptides involved in the activation of the 
autoaggressive T cells. Thus, our panel of well-characterized 
T cell hybridomas i  an extremely powerful tool to map and 
define the arthritogenic peptides involved in the disease in- 
duction. Currently, experiments designed to elute and se- 
quence peptides bound in the MHC cleft using tandem ass 
spectrometry are in progress (39). Moreover, full character- 
ization of the CIA autoimmune disease model may provide 
a basis towards future therapeutic strategies for preventive 
medicine in humans. 
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